Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study

Summary

Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy. The objective of the study is to assess right-hand motor activation in MSA patients before and after an acute levodopa challenge and to compare these data with those obtained in patients with Parkinson Disease (PD) and healthy volunteers (HV).

Methods: Eighteen MSA patients, eight PD patients and 10 age-matched HV will be included. rCBF measurements with H215O PET will be performed at rest and during a right hand movement. Statistical parametric mapping will be used to analyze motor versus rest in OFF and ON condition and effect of levodopa on motor activation.

Hypothesis: MSA and PD patient should recruited different motor networks.

Conditions

• Multisystemic Atrophy

Interventions

RADIATION

H215O PET

H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.

DRUG

Levodopa

Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.

Sponsors & Collaborators

• University Hospital, Toulouse

  lead OTHER

Principal Investigators

• Olivier Rascol, MD PHD · University Hospital, Toulouse

• Pierre Payoux, MD PhD · University Hospital, Toulouse

• Olivier Rascol, MD PhD · University Hospital, Toulouse

• Franck Durif, MD PhD · University Hospital, Clermont-Ferrand

• Jean-Philippe Azulay, MD PhD · University Hospital, Marseille

• François Tison, MD PhD · University Hospital, Bordeaux

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2002-05-31

Primary Completion

2005-05-31

Completion

2006-05-31

Countries

• France

Study Locations